Read Time: 3 minutes
An extensive tumor genomic analysis of individuals with ovarian cancer, led by researchers from Huntsman Cancer Institute at the (the U) and , revealed that Black women have nearly identical mutations to other previously studied populations. But researchers also found a few notable differences that may be clinically relevant.
鈥淥ur analysis shows the importance of researching different types of populations,鈥 says , co-principal investigator of the study and co-leader of the at Huntsman Cancer Institute and professor of population health sciences at the U. 鈥淭he molecular features that we discover in one patient group will allow us to find potential targets for drug therapies that will work for all patients and improve ovarian cancer health care for everyone.鈥
Ovarian cancer is often diagnosed in its later stages due to a lack of clear symptoms or an effective screening approach, according to the National Cancer Institute. Over 12,000 women are estimated to have died from the disease in 2024. Extensive federal and private research has been devoted to understanding the causes and optimal treatment regimens for this deadly type of disease.
The study included individuals between 20 to 79 years of age who had been diagnosed with high-grade serous ovarian cancer, the most common ovarian cancer. State-of-the-art tumor sequencing technology was used to discern tumor characteristics.
鈥淛ust because KRAS may be more prevalent in Black individuals does not mean it is not present in all populations with this cancer type. If validated, this could be a missed treatment opportunity.鈥
Molecular epidemiologist , a recent graduate from the U鈥檚 Population Health Sciences doctoral program, is the first author of the study.
鈥淧rior characterizations, or analyses, of mutations in ovarian cancers were done in predominantly white populations,鈥 says Lawson-Michod. 鈥淭his project was unique in that it was the first large study to characterize tumor mutations in Black individuals with high-grade serous ovarian cancer.鈥
The team compared the results of their research to those of the (TCGA), a National Cancer Institute-initiated landmark genomics database that characterized the genetic makeup of 33 cancer types. Most of the high-grade serous ovarian cancer samples analyzed in TCGA were from white individuals.
The researchers wanted to understand if there were differences in the tumors of certain populations given differences in survival.
鈥淭he characterizations between these groups showed similar mutations. But Black individuals have a 43% five-year overall survival rate for ovarian cancer, compared to 51% for all American women,鈥 says Doherty. 鈥淥ur research shows that this discrepancy is unlikely to be explained by the genetic makeup of the tumors themselves.鈥
鈥淥ur analysis shows the importance of researching different types of populations.鈥
Still, the research team did note a few key differences.
In the analysis of Black individuals, were more prevalent than in white individuals. KRAS is a mutated gene that causes cancer.
鈥KRAS did not show up as a significant mutation in the high-grade serous ovarian cancer patients from TCGA,鈥 says Lawson-Michod. 鈥淗owever, just because KRAS may be more prevalent in Black individuals does not mean it is not present in all populations with this cancer type. If validated, this could be a missed treatment opportunity.鈥
Researchers also noted that Black women in the study had a higher prevalence of homologous recombination deficiency (HRD). HRD prevents damaged cells from repairing themselves. HRD tumors are sensitive to , a type of targeted therapy.
鈥淗RD status is associated with better survival, but Black women have higher mortality rates from this disease than other women,鈥 says , co-principal investigator of the study, member of the Cancer Prevention and Control Research Program at of , and professor of epidemiology at Emory University. 鈥淭his characterization of ovarian cancer in an understudied population such as this can hopefully impact clinical decision-making for all women with ovarian cancer and inform targeted treatment for this disease.鈥
鈥淭his can hopefully impact clinical decision-making for all women with ovarian cancer and inform targeted treatment for this disease.鈥
The have been published in , a journal of the .
The research described in this release is supported by the National Institutes of Health/National Cancer Institute including P30 CA042014, and Huntsman Cancer Foundation.
Media Contact
Heather Simonsen
Public Affairs Senior Manager
Huntsman Cancer Institute
801 581-3194
public.affairs@hci.utah.edu
About Huntsman Cancer Institute at the University of Utah
Huntsman Cancer Institute at the is the National Cancer Institute-designated Comprehensive Cancer Center for Utah, Idaho, Montana, Nevada, and Wyoming. With a legacy of innovative cancer research, groundbreaking discoveries, and world-class patient care, we are transforming the way cancer is understood, prevented, diagnosed, treated, and survived. Huntsman Cancer Institute focuses on delivering the most advanced cancer healing and prevention through scientific breakthroughs and cutting-edge technology to advance cancer treatments of the future beyond the standard of care today. We have more than 300 open clinical trials and 250 research teams studying cancer. More genes for inherited cancers have been discovered at Huntsman Cancer Institute than at any other cancer center. Our scientists are world-renowned for understanding how cancer begins and using that knowledge to develop innovative approaches to treat each patient鈥檚 unique disease. Huntsman Cancer Institute was founded by Jon M. and Karen Huntsman.
Resources for Media
The critical research happening every day at Huntsman Cancer Institute is supported by the National Institutes of Health/National Cancer Institute, including cancer center support grant P30 CA042014, as well as Huntsman Cancer Foundation.